Literature DB >> 21573978

¹⁸F-Fluorocholine integrated PET/MRI for the initial staging of prostate cancer.

Martin Lord1, Osman Ratib, Jean-Paul Vallée.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21573978     DOI： 10.1007/s00259-011-1837-6

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  5 in total

Review 1.  Computed tomography--an increasing source of radiation exposure.

Authors:  David J Brenner; Eric J Hall
Journal:  N Engl J Med       Date:  2007-11-29       Impact factor: 91.245

2.  The role of staging CT scans in the treatment of prostate cancer: a retrospective audit.

Authors:  R J Burcombe; P J Ostler; A W Ayoub; P J Hoskin
Journal:  Clin Oncol (R Coll Radiol)       Date:  2000       Impact factor: 4.126

Review 3.  Generalized lymphadenopathy.

Authors:  H Libman
Journal:  J Gen Intern Med       Date:  1987 Jan-Feb       Impact factor: 5.128

4.  Prospective comparison of 18F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer.

Authors:  S Adams; R P Baum; T Stuckensen; K Bitter; G Hör
Journal:  Eur J Nucl Med       Date:  1998-09

5.  Evaluation of [(18)F]-choline PET/CT for staging and restaging of prostate cancer.

Authors:  Daniela B Husarik; Raymond Miralbell; Markus Dubs; Hubert John; Olivier T Giger; Albert Gelet; Tibor Cservenyàk; Thomas F Hany
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-10-10       Impact factor: 9.236
  5 in total
  6 in total

Review 1.  Imaging of prostate cancer with PET/CT using (18)F-Fluorocholine.

Authors:  Reza Vali; Wolfgang Loidl; Christian Pirich; Werner Langesteger; Mohsen Beheshti
Journal:  Am J Nucl Med Mol Imaging       Date:  2015-01-15

Review 2.  Sequential whole-body PET/MR scanner: concept, clinical use, and optimisation after two years in the clinic. The manufacturer's perspective.

Authors:  Antonis Kalemis; Bénédicte M A Delattre; Susanne Heinzer
Journal:  MAGMA       Date:  2012-08-07       Impact factor: 2.310

3.  Comparison of PET/CT and PET/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience.

Authors:  A Afshar-Oromieh; U Haberkorn; H P Schlemmer; M Fenchel; M Eder; M Eisenhut; B A Hadaschik; A Kopp-Schneider; M Röthke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-12-19       Impact factor: 9.236

Review 4.  Imaging biomarkers in prostate cancer: role of PET/CT and MRI.

Authors:  M Picchio; P Mapelli; V Panebianco; P Castellucci; E Incerti; A Briganti; G Gandaglia; M Kirienko; F Barchetti; C Nanni; F Montorsi; L Gianolli; S Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-01-17       Impact factor: 9.236

Review 5.  Initial prostate cancer diagnosis and disease staging--the role of choline-PET-CT.

Authors:  Paola Mapelli; Maria Picchio
Journal:  Nat Rev Urol       Date:  2015-08-11       Impact factor: 14.432

6.  Can Choline PET Tackle the Challenge of Imaging Prostate Cancer?

Authors:  Hossein Jadvar
Journal:  Theranostics       Date:  2012-03-16       Impact factor: 11.556
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.